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Smart drug delivery systems that are triggered by environmental conditions have been developed to enhance cancer
therapeutic efficacy while limiting unwanted effects. Because cancer exhibits abnormally high local acidities compared
to normal tissues (pH 7.4) due to Warburg effects, pH-sensitive systems have been researched for effective cancer
therapy. Chitosan-based intelligent theragnosis nanocomposites, N-naphthyl-O-dimethymaleoyl chitosan-based
drug-loaded magnetic nanoparticles (NChitosan-DMNPs), were developed in this study. NChitosan-DMNPs are capable
of pH-sensitive drug release with MR-guided images because doxorubicin (DOX) and magnetic nanocrystals (MNCs) are
encapsulated into the designed N-naphthyl-O-dimethymaleoyl chitosan (N-nap-O-MalCS). This system exhibits rapid
DOX release as acidity increases, high stability under high pH conditions, and sufficient capacity for diagnosing and
monitoring therapeutic responses. These results demonstrate that NChitosan-DMNPs have potential as theragnosis
nanocomposites for effective cancer therapy.
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Many therapeutic anticancer drugs are limited in their clin-
ical applications because of their toxicities and low solubil-
ity in aqueous media [1-14]. For instance, doxorubicin
(DOX) is one of the most widely used drugs in cancer ther-
apy. However, it can cause side effects such as cardiotoxi-
city and drug resistance. Also, it is difficult to administer
intravenously because of its low solubility in aqueous
media. Nanomaterial-based drug delivery systems have re-
ceived attention in overcoming this drawback. These sys-
tems can be made from a variety of organic and inorganic
materials including non-degradable and biodegradable
polymers, and inorganic nanocrystals. Polymeric micelles
based on amphiphilic block copolymers have the advan-
tages of high biocompatibility and drug-loading capacity
with low toxicity because they can self-assemble into* Correspondence: sjchung@dongguk.edu; ymhuh@yuhs.ac
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in any medium, provided the original work is ppolymeric micelles in aqueous media [8,15-17]. They accu-
mulate in tumors through an enhanced permeation and re-
tention (EPR) effect compared to single small molecules,
leading to preferential spatio-distribution in the tumor.
However, the drug release behavior of polymeric micelles is
difficult to control; they freely release the drug before
reaching tumors, which could give rise to unwanted side
effects and low therapeutic efficacy [4,8]. Well-designed
drug delivery systems need to be developed to enable
cancer chemotherapy that fundamentally enhances thera-
peutic efficacy by minimizing drug release in undesirable
sites. With these systems, a precise drug concentration can
be delivered to tumors to reduce side effects. Drug delivery
systems can be designed to release drugs triggered by envir-
onmental parameters such as pH, enzymes, and temperature
[16,18-29]. The pH-sensitive systems are of special interest
because tumors and intracellular endosomal/lysomal com-
partments exhibit abnormally high local acidities compared
to healthy tissues with a normal physiological pH of 7.4
[9,21,25,28-43].
In this study, chitosan-based intelligent theragnosis
nanocomposites that enable pH-sensitive drug releasepen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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veloped (Figure 1). This nanocomposite was based on
N-naphthyl-O-dimethymaleoyl chitosan (N-nap-O-
MalCS), a newly synthesized, pH-sensitive amphiphilic
copolymer modified by maleoyl groups on a chitosan
backbone. Chitosan is non-toxic, biodegradable, and
non-immunogenic [44-72]. It is a linear polysaccharide
consisting of N-acetyl-glucosamine (acetylated) and glu-
cosamine (deacetylated) repeating units, and its abun-
dant reactive groups facilitate chemical modification of
functional groups. Hydrophobic magnetic nanocrystals
were loaded as imaging agents in this system, leading to
the formulation of theragnosis nanocomposites capable
of delivery therapy concomitant with monitoring. This
nanocomposite will allow effective cancer therapy be-
cause it can provide patient-specific drug administration
strategies that consider drug-release patterns and
biodistribution.
Methods
Materials
Chitosan with an average molecular weight (mol. wt.) of
15 kDa was purchased from Seafresh Industry Public
Co., Ltd. (Bangkok, Thailand). The degree of chitosan
deacetylation (DDA) was determined by 1H-NMR spec-
troscopy to be 98%. Cellulose microcrystalline power,
chitosan with low molecular weight, 2-naphthaldehyde,
2,3-dimethylmaleic anhydride, sodium borohydride,Figure 1 Schematic illustration of NChitosan-DMNPs enabling pH-sensodium hydroxide (NaOH), triethylamine, N,N-dimethyl-
formamide (DMF), dimethylsulfoxide (DMSO), N-hydro-
xysulfosuccinicimide (NHS), iron(III) acetylacetonate,
manganese(II) acetylacetonate, 1,2-hexadecanediol, do-
decanoic acid, dodecylamine, benzyl ether, paraformalde-
hyde, triethylamine, 2,3-dimethylmaleic anhydride, and
DOX were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Ethanol and chloroform (CF) were obtained
from Duksan Pure Chemicals Co. (Seonggok-dong,
Danwon-gu, South Korea). Dialysis tubing with a mo-
lecular weight cutoff of 3,500 g/mol was purchased from
Cellu Sep T4, Membrane Filtration Products, Inc.
(Segiun, TX, USA). Phosphate buffered saline (PBS;
10 mM, pH 7.4) and Dulbecco’s modified eagle medium
(DMEM) were purchased from Gibco (Life Technologies
Corp., Carlsbad, CA, USA). All other chemicals and re-
agents were of analytical grade.
Synthesis of N-naphthyl-O-dimethylmaleoyl chitosan
N-naphthyl chitosan (N-NapCS) was synthesized by re-
ductive amination (Figure 2a) [68]. Briefly, 1.00 g of
chitosan (6.17 meq/GlcN) was dissolved in 50 mL of 1%
(v/v) acetic acid (pH 4). 2-Naphthaldehyde (1.31 mL,
2.0 meq/N-NapCS) dissolved in 30 mL of DMF was then
added and stirred at room temperature for 24 h.
Solution pH was adjusted to 5 with 15% (w/v) NaOH.
Subsequently, 3.50 g of sodium borohydride (15 meq/N-
NapCS) was added and stirred at room temperature forsitive drug release and MR monitoring for cancer therapy.
Figure 2 Synthesis of (a) N-NapCS and (b) N-naphthyl-O-dimethylmaleoyl chitosan (N-nap-O-MalCS).
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NaOH. The precipitate was collected by filtration and
re-dispersed in ethanol several times to remove excess
aldehyde. The precipitate was then filtered, washed with
ethanol, and dried under vacuum. White N-NapCS pow-
der was obtained (1.78 g). Each N-NapCS (0.50 g) was
dispersed in 30 mL of DMF/DMSO (1:1 v/v). Triethyla-
mine with the amount of 1 mL and 1.50 g of 2,3-
dimethylmaleic anhydride were added. The reaction
was performed at 100°C under argon purge for 24 h
(Figure 2b). The reaction mixture was cooled to room
temperature and filtered to remove insoluble residue.
The mixture was dialyzed with distilled water for 3 days
to remove excess 2,3-dimethylmaleic anhydride and
solvent. It was then freeze-dried at −85°C under vacuum
conditions for 24 h. A brown N-nap-O-MalCS powder
was obtained (0.58 g).
Preparation of nanopolymeric micelles
N-Nap-O-MalCS (12 mg) was dissolved in 12 mL of
DMSO. The solution was stirred at room temperature
until completely dissolved. It was then placed into a dialy-
sis bag and dialyzed against deionized water overnight.
The solution was then filtered through syringe filter mem-
branes (cellulose acetate) with pore sizes of 0.45 μm for
further study. Using the same procedure described above,
the solution was then placed into a dialysis bag and dia-
lyzed against deionized water by adjusting to pH of 8 to 9
with 5% (w/v) sodium hydroxide overnight.Effect of pH and temperature on nanopolymeric micelles
Three milliliters of nanopolymeric micelles was placed
into a dialysis bag and dialyzed against 12 mL of PBS
buffer of pH 5.5, 6.0, 6.5, 6.8, 7.2, 7.4, and 8.0 at 25 and
37°C for 24 h. PBS buffer was refreshed twice. The par-
ticle sizes of nanopolymeric micelles with different pH
values were analyzed in triplicate by laser scattering.
Preparation of magnetic nanocrystals
Monodispersed magnetic nanocrystals that are soluble in
non-polar organic solvents were synthesized by thermal
decomposition, as previously described [73-78]. Briefly,
iron(III) acetylacetonate (2 mmol), manganese(II) acetyl-
acetonate (1 mmol), 1,2-hexadecanediol (10 mmol), do-
decanoic acid (6 mmol), and dodecylamine (6 mmol) were
dissolved in benzyl ether (20 mL) under an ambient nitro-
gen atmosphere. The mixture was then preheated to 200°C
for 2 h and refluxed at 300°C for 30 min. After reactants
cooled down at room temperature, the products were puri-
fied with excess pure ethanol. Approximately 12 nm of
magnetic nanocrystals (MNCs) were synthesized by seed-
mediated growth method.
Preparation of N-naphthyl-O-dimethymaleoyl chitosan-
based drug-loaded magnetic nanoparticles
N-naphthyl-O-dimethymaleoyl chitosan-based drug-
loaded magnetic nanoparticles (NChitosan-DMNPs)
were fabricated by nanoemulsion methods. Fifty milli-
grams of MNCs and 2 mg DOX were dissolved in 4 mL
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50 mL of pH 9.8 solution containing N-nap-O-MalCS
(40 mg). The solution was ultrasonicated for 30 min and
stirred overnight at room temperature to evaporate the
CF. The resulting suspension was centrifuged three
times for 15 min at 13,000 rpm. After the supernatant
was removed, the precipitated NChitosan-DMNPs were
re-dispersed in 5 mL of deionized water. The size distri-
bution and zeta potential of NChitosan-DMNPs were
analyzed by laser scattering (ELS-Z; Otsuka Electronics,
Hirakata, Osaka, Japan). The loading ratio (%) and crys-
tallinities of MNCs at 25°C were determined by thermo-
gravimetric analysis (SDT-Q600, TA Instruments, New
Castle, DE, USA) and X-ray diffraction (X-ray diffract-
ometer Ultima3; Rigaku Corporation, Tokyo, Japan),
respectively. The magnetic properties of NChitosan-
DMNPs were also analyzed using vibration sample mag-
netometer (VSM) (model 7407, Lake Shore Cryotonics
Inc, Westerville, Columbus, OH, USA) at 25°C. The sur-
face compositions were measured using X-ray photoelec-
tron spectrometry (ESCALAB 250 XPS spectrometer;
Thermo Fisher Scientific, Hudson, NH, USA).
Determination of drug release profile
One milliliter of the above NChitosan-DMNPs was cen-
trifuged for 45 min at 20,000 rpm, and the precipitated
NChitosan-DMNPs were re-dispersed in 1 mL of buffer
solutions at pH 5.5, 7.4, and 9.8. The dispersed particles
were sealed in dialysis tubing and immersed in 10 mL of
each buffer solution at 37.5°C, which was conducted in
triplicate. The amount of released drug was measured at
593 nm by fluorescence spectrometry. These results are
shown as average ± standard deviation (n = 3). In
addition, the drug loading efficiency (7.2 wt.%) was mea-
sured in the same manner. Briefly, NChitosan-DMNPs’
weight was measured after lyophilization and then dis-
solved in 1 mL of DMSO. The loaded amount of drug
was measured by fluorescence spectrometry, using the
following formula:
Drug loadingeffiency wt:%ð Þ
¼ Weightof drug inNChitosan‐DMNPsð Þ=
WeightofNChitosan‐DMNPsð Þ  100
Cellular internalization of NChitosan-DMNPs
MR imaging and fluorescence microscopy confirmed
cellular internalization of NChitosan-DMNPs. NIH3T6.7
cells were obtained from American Type Culture Collec-
tion. First, these cells were seeded at a density of 1.0 ×
106 cells/well in six wells for growth overnight at 37°C
and then further incubated with NChitosan-DMNPs in
5% CO2 for 24 h at 37°C. The cells were washed three
times with PBS and stained by Hoechst (MolecularProbes TM, OR, USA) to show nucleus location. Fluor-
escence microscopic images were obtained using a laser
scanning confocal microscope (LSM700, Carl Zeiss,
Jena, Germany). Under the same conditions, NIH3T6.7
cells treated with NChitosan-DMNPs were washed
twice, collected, and then re-suspended in 0.2 mL of 4%
paraformaldehyde for MR imaging analysis. All experi-
ments were conducted in triplicate.
Determination of cell viability using MTT assay
The cell viability of NChitosan-DMNPs was evaluated by
measuring cell growth inhibition using a 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay (Roche Molecular Biochemicals, Mannheim,
Germany) compared to DOX as a control. NIH3T6.7
cells (1.0 × 104 cells/well) were implanted in a 96-
microwell plate with temperature at 37°C overnight and
treated with various concentrations of NChitosan-
DMNPs. After 24 h, the cells were washed and incu-
bated for an additional 48 h. The yellow tetrazolium salt
of MTT solution was reduced to purple formazan
crystals in metabolically active cells. The cell viability
was determined from the ratio of treated cells to non-
treated control cells. The results are shown as average ±
standard deviation (n = 4).
Animal experiments
All animal experiments were conducted with approval
from the Association for Assessment and Accreditation
of Laboratory Animal Care (AAALAC) International.
Tumor-bearing mice were developed, and NIH3T6.7
cells (5 × 106 cells suspended in 50 μL saline per animal)
were implanted into the proximal thighs of female
BALB/nude mice (4 to 5 weeks of age) to investigate
NChitosan-DMNPs’ distribution and tumor growth rate.
After tumor volume reached approximately 40 mm3 at
3 days post-implantation (0 days), in vivo magnetic res-
onance imaging (MRI) experiments were performed
using NChitosan-DMNPs (five mice). Comparative
therapeutic efficacy was evaluated using three groups
(saline, doxorubicin, and NChitosan-DMNP) of mice
(ten mice per each group). Animals were treated with
equivalent doses of DOX (3 mg/kg) and NChitosan-
DMNPs suspended in PBS by intravenous injection
every 2 days for 12 days. At predetermined time periods,
the length of the minor axis (2a) and major axis (2b) of
each tumor was measured using a caliper. Each tumor
volume was then calculated using the formula for ellips-
oid [(4/3)π × a2b].
MR imaging
In vivo MR imaging experiments were performed using a
3.0 T clinical MRI instrument with a micro-47 surface coil
(Intera; Philips Medical Systems, Best, The Netherlands).
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were measured by Carr-Purcell-Meiboom-Gill sequence at
room temperature with the following parameters: TR = 10 s,
echoes = 32 with 12 ms even echo space, number of acquisi-
tions = 1, point resolution = 156 × 156 μm, and section
thickness = 0.6 mm. For T2-weighted MR imaging in the
nude mouse model, the following parameters were adopted:
resolution = 234 × 234 μm2, section thickness = 2.0 mm,
TE = 60 ms, TR = 4,000 ms, and number of acquisitions = 1.
Results and discussion
Characterization of N-naphthyl-O-dimethymaleoyl chitosan
N-naphthyl-O-dimethymaleoyl chitosan was synthesized
by modifying chitosan with naphthyl groups at amino
groups to complement their solubility and introduce
amphiphilic properties [79]. Chitosan was reacted with
naphthaldehyde to obtain an imine (Schiff base), which
is easily converted into an N-naphthyl derivate by reduc-
tion with sodium borohydride or sodium cyanoborohy-
dride (Figure 2a). Afterward, N-NapCS was introduced
into the hydroxyl groups of chitosan by maleoylation
with dimethylmaleic anhydride in DMF/DMSO to obtain
N-nap-O-MalCS (Figure 2b) [67,68]. This synthetic com-
pound was characterized by a 1H-NMR spectrum, and
satisfactory analysis data were obtained (Figure 3). N-
nap-O-MalCS was used to form nanopolymeric micelles
by dialysis in various pH solutions. They were less than
200 nm at pH 7.2 to 8.0 but rapidly increased in size asFigure 3 1H-NMR spectrum of N-nap-O-MalCS. (a) -CH- in aromatic ringthe acidity of solution increased (Figure 4). Their sizes
could not be measured at pH 5.5 and 6.0 (Figure 4a) due to
aggregation. This was a result of the weakened solubility of
N-nap-O-MalCS in the aqueous phase caused by acid hy-
drolysis of its maleoyl groups [80,81]. This phenomenon
accelerated at 37°C compared to 25°C (Figure 4b). N-Nap-
O-MalCS has a potential as a drug carrier because it can
self-assemble with pH-sensitive behavior [67,68,79,82].
Characterization of N-naphthyl-O-dimethymaleoyl
chitosan-based drug-loaded magnetic nanoparticles
NChitosan-DMNPs were prepared by a nanoemulsion
method, in which naphtyl groups were absorbed on the
hydrophobic surface of MNCs and DOX mainly caused by
van der Waals force, and both their oxygen atoms and
water molecules were interacted by hydrogen bonding.
This interaction could lead to formation of NChitosan-
DMNPs dispersed in aqueous phase with high colloidal
stability. NChitosan-DMNPs were loaded with 27.5 wt.%
MNCs and exhibited superparamagnetic behavior with a
magnetization saturation value of 40.4 emu/gFe + Mn at
1.2 T (Figure 5). In addition, iron (Fe) and manganese
(Mn) were not detected by X-ray photoelectron spec-
troscopy (XPS) analysis, which indicates that MNCs
were safely encapsulated inside the NChitosan-DMNPs
(Figure 5). The availability of NChitosan-DMNPs as MRI
contrast agents was evaluated by measuring spin-spin re-
laxation times (T2) of water protons in the aqueous. (b) -CH2-. (c) -CH. (d) -CH3.
Figure 4 Effect of N-nap-O-MalCS polymeric micelles in various pH conditions and temperatures. (a) Stability. (b) Particle size.
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MNCs (Fe +Mn) in NChitosan-DMNPs increased, the
MR image was proportionally darkened with an R2 coeffi-
cient of 254.6/mMs, demonstrating that NChitosan-
DMNPs have sufficient ability as MRI contrast agents
(Figure 6).
pH-sensitive drug release properties
To investigate the pH-dependent behavior of NChito-
san-DMNPs, they were dispersed in different pH solu-
tions (pH 5.5, 7.4, and 9.8) and their sizes were analyzed
using laser scattering. NChitosan-DMNPs in a pH 9.8
solution showed stable particle size around 100 nm
(100.3 ± 4.9 nm), but their sizes increased slightly with
increased buffer solution acidity (pH 5.5, 185.3 ±
13.5 nm and pH 7.4, 158.8 ± 10.6 nm) (Figure 7a)
[17,20,30,83,84]. This is because the solubility of N-nap-
O-MalCS of NChitosan-DMNPs was weakened by acid
hydrolysis of maleoyl groups, as mentioned above. This
pH-dependent behavior was expected to induce pH-
sensitive drug release profiles. DOX was abruptly re-
leased from NChitosan-DMNPs under acidic conditions(pH 5.5) with about 90% of drug release within 24 h
(Figure 7b), whereas only 20% of DOX was released at
higher pH conditions (pH 7.4 and 9.8) during the same
time period and both release profiles showed sustained
release patterns for 8 days. This result implies that drugs
could be released more from NChitosan-DMNPs in
acidic tumor sites than in normal tissues with decreased
drug loss during blood circulation. After NChitosan-
DMNPs internalization by endocytosis, drug release
could be further accelerated inside the acidic endosomes
of tumor cells.
Cellular uptake and cytotoxicity
NIH3T6.7 cells were treated with NChitosan-DMNPs
and observed by confocal laser fluorescence microscopy to
confirm their cellular uptake. Blue fluorescence indicated
cell nuclei by Hoechst stains and red fluorescent signals
are derived from cell nuclei and DOX. In Figure 8a, red
fluorescence was generally observed in the intracellular
regions, indicating released DOX from internalized NChi-
tosan-DMNPs. NIH3T6.7 cells incubated with NChitosan-
DMNPs also showed MR contrast effects compared to
Figure 5 Characterizations of NChitosan-DMNPs. (a) Thermogravimetric analysis (TGA), (b) magnetic hysteresis loops, and (c) XPS patterns of
N-naphtyl-O-dimethymaleoyl chitosan-based drug-loaded magnetic nanoparticles (NChitosan-DMNPs).
Figure 6 Assessment of the ability of NChitosan-DMNPs as MRI contrast agents. (a) T2-weighted MR images of NChitosan-DMNPs in
aqueous solution and (b) relaxation rate (R2) versus NChitosan-DMNPs concentration.
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Figure 7 Particle size of NChitosan-DMNPs in different pH conditions (a) and pH-sensitive drug release profiles (b). Red pH 5.5, blue
pH 7.4, and green pH 9.8.
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signal of NIH3T6.7 cells treated with NChitosan-DMNPs
was about 1.72-fold higher than that of non-treated cells,
with an R2 value of 22.1/s (R2 value of non-treated cells:
8.10/s). The cytotoxicity of NChitosan-DMNPs against
NIH3T6.7 cells was evaluated by MTT assay (Figure 9)
[85-87]. DOX-treated cells were also evaluated under the
same conditions as a control.
DOX and NChitosan-DMNPs exhibited dose-
dependent cytotoxic effects on NIH3T6.7. DOX showedFigure 8 Cellular internalization efficacy of NChitosan-DMNPs. (a) Fluo
blue filter for Hoechst; iii, red filter for DOX). (b) T2-weighted MR image an
Scale bars 50 μm.a higher cytotoxicity than NChitosan-DMNPs because
NChitosan-DMNPs released DOX after their cellular in-
ternalization, while free DOX directly diffused and pene-
trated through cell membranes due to its low molecular
weight.
In vivo theranostic effects of NChitosan-DMNPs
The theranostic effects of NChitosan-DMNPs were con-
firmed against an in vivo model [9,88,89]. To determine
the therapeutic dosing schedule, intratumoral distributionsrescence image of NChitosan-DMNP-treated cells (i, merged image; ii,
d graph of △R2/R2 non-treatment for NChitosan-DMNP-treated cells.
Figure 9 Cell viability test of cells treated with DOX and
NChitosan-DMNPs (red, NChitosan-DMNPs; blue, DOX).
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tigated through MR images after intravenous injection
into mouse tail veins (150 μg Fe +Mn, 3 mg/kg DOX).
After injecting NChitosan-DMNPs (post-injection), the
black color gradually spread out in T2-weighted MR im-
ages following the peripheral blood vessels of the tumor
area. This resulted from diffusion and permeation to
tumor tissues across corresponding vascular distributions
by an EPR effect (Figure 10a). The therapeutic dosing of
NChitosan-DMNPs were determined because these were
maximally delivered within 1 h at the tumor sites and then
over 80% of drug was released in the in the acidic environ-
ments within the tumor for 24 h, as judged from in vivoFigure 10 MR imaging to assess intratumoral distributions of NChitos
efficacy. (a) T2-weighted MR images of tumor-bearing mice after intraveno
yellow line boundary. (b) Comparative therapeutic efficacy study in the in
arrowheads indicate the therapeutic dosing schedule of each therapeutic cMRI and drug release profiling studies. Considering these
results, we determined 2 days periodically to consistently
maintain drug concentration within tumors for effective
cancer therapy. NChitosan-DMNPs, free DOX, and saline
were administrated to each subgroup of tumor-bearing
mice via intravenous (i.v.) injection every 2 days for 12 days
(injection on days 0, 2, 4, 6, 8, 10, and 12). Tumor sizes
were monitored for 24 days. NChitosan-DMNPs exhibited
significant tumor growth inhibition with an average tumor
growth rate of 1,638.1 ± 306.9% compared to the control
(free DOX and saline) groups (saline, 4,642.8%; free DOX,
2,991.9%) (Figure 10b). Although NChitosan-DMNPs
could not completely suppress tumor growth, tumor
growth inhibition was more effective than with saline or
free DOX. During the experimental period, no loss in mice
body weight was observed.Conclusions
We have formulated theranostic nanocomposites,
NChitosan-DMNPs, based on N-nap-O-MalCS for ef-
fective cancer therapy. NChitosan-DMNPs exhibited a
pH-sensitive drug release pattern with MR imaging due
to the pH-sensitive properties of N-nap-O-MalCS. Fur-
thermore, theragnostic efficacies of NChitosan-DMNPs
were confirmed in the in vivo model by determining
their therapeutic dosing schedule based on drug release
profiling and in vivo MRI study. From these results,
NChitosan-DMNPs are expected to play a significant
role in the dawning era of personalized medicine.an-DMNPs in tumor-bearing mice and comparative therapeutic
us injection of NChitosan-DMNPs. Tumor regions are indicated with a
vivo model (black, NChitosan-DMNPs; gray, DOX; white, saline). Red
ondition (NChitosan-DMNPs, DOX, and saline).
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